DE69835085D1 - Regulation der transcription in säugetierzellen und viraler replikation durch eine tetracyclinrepressor - Google Patents

Regulation der transcription in säugetierzellen und viraler replikation durch eine tetracyclinrepressor

Info

Publication number
DE69835085D1
DE69835085D1 DE69835085T DE69835085T DE69835085D1 DE 69835085 D1 DE69835085 D1 DE 69835085D1 DE 69835085 T DE69835085 T DE 69835085T DE 69835085 T DE69835085 T DE 69835085T DE 69835085 D1 DE69835085 D1 DE 69835085D1
Authority
DE
Germany
Prior art keywords
repressor
mammalian cells
tetracyclinrepressor
transcription
regulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69835085T
Other languages
English (en)
Other versions
DE69835085T2 (de
Inventor
Feng Yao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Application granted granted Critical
Publication of DE69835085D1 publication Critical patent/DE69835085D1/de
Publication of DE69835085T2 publication Critical patent/DE69835085T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69835085T 1997-06-26 1998-05-29 Regulation der transcription in säugetierzellen und viraler replikation durch eine tetracyclinrepressor Expired - Lifetime DE69835085T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/883,327 US5972650A (en) 1997-06-26 1997-06-26 Tetracycline repressor regulated mammalian cell transcription and viral replication switch
US883327 1997-06-26
PCT/US1998/010907 WO1999000510A1 (en) 1997-06-26 1998-05-29 Regulation of transcription in mammalian cells and viral replication by a tetracyclin repressor

Publications (2)

Publication Number Publication Date
DE69835085D1 true DE69835085D1 (de) 2006-08-10
DE69835085T2 DE69835085T2 (de) 2007-01-18

Family

ID=25382404

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69835085T Expired - Lifetime DE69835085T2 (de) 1997-06-26 1998-05-29 Regulation der transcription in säugetierzellen und viraler replikation durch eine tetracyclinrepressor

Country Status (7)

Country Link
US (3) US5972650A (de)
EP (1) EP0990041B1 (de)
JP (3) JP3577323B2 (de)
AT (1) ATE331800T1 (de)
CA (1) CA2293612C (de)
DE (1) DE69835085T2 (de)
WO (1) WO1999000510A1 (de)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972650A (en) * 1997-06-26 1999-10-26 Brigham And Women's Hospital Tetracycline repressor regulated mammalian cell transcription and viral replication switch
AU4924199A (en) * 1998-07-30 2000-02-21 Advec, Inc. Repressor proteins producing cell lines for the propagation of vectors
EP1135461A4 (de) 1998-12-02 2003-03-26 Univ Boston Gen-netzwerke zur kontrolle der genexpression
JP2003506047A (ja) * 1999-07-30 2003-02-18 ユニバーシティ カレッジ ロンドン マイクロカプセル封入した酸化窒素シンターゼ源
EP1083230A1 (de) * 1999-09-10 2001-03-14 Academisch Medisch Centrum Amsterdam Virale Replikons und von induzierenden Wirkstoffen abhängige Viren
GB0015090D0 (en) * 2000-06-20 2000-08-09 Implyx Ltd Gene-activating conjugates
AU2001288682A1 (en) 2000-08-30 2002-03-13 Chemocentryx, Inc. Inhibition of cmv infection and dissemination
WO2002020811A2 (en) * 2000-09-09 2002-03-14 Basf Plant Science Gmbh Modified tet-inducible system for regulation of gene expression in plants
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
EP1364037A4 (de) * 2001-02-02 2005-08-03 Chemocentryx Inc Verfahren und zusammensetzungen zur stimulierung einer immunantwort
GB0106786D0 (en) * 2001-03-19 2001-05-09 Gendaq Ltd Gene regulation
WO2002088346A2 (en) * 2001-05-01 2002-11-07 National Research Council Of Canada A system for inducible expression in eukaryotic cells
ATE527347T1 (de) * 2001-08-02 2011-10-15 Inst Clayton De La Rech Verfahren und zusammensetzungen im zusammenhang mit verbesserten lentivirusvektor- produktionssystemen
JP2005503797A (ja) * 2001-09-13 2005-02-10 ジェンベク、インコーポレイティッド アデノウイルスベクター及び関連する系、並びに製造及び使用の方法
NZ532060A (en) 2001-10-02 2005-11-25 Inst Clayton De La Rech Methods and compositions relating to restricted expression lentiviral vectors and their applications
ES2439874T3 (es) * 2002-05-29 2014-01-27 Regeneron Pharmaceuticals, Inc. Sistema de expresión en eucariotas inducible
US8673589B2 (en) 2002-05-29 2014-03-18 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
CA2498130A1 (en) * 2002-09-05 2004-03-18 Invitrogen Corporation Compositions and methods for synthesizing nucleic acids
US20050071893A1 (en) * 2002-10-17 2005-03-31 Jost Seibler SiRNA mediated gene silencing in transgenic animals
EP1563069B1 (de) * 2002-11-22 2012-06-06 Institut Clayton De La Recherche Zusammensetzungen und systeme zur genregulierung
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
EP2418281B1 (de) 2003-10-24 2016-06-01 Gencia Corporation Verfahren und Zusammensetzungen zur Abgabe von Polynukleotiden
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US20050164210A1 (en) * 2004-01-23 2005-07-28 Vivek Mittal Regulated polymerase III expression systems and related methods
US9273326B2 (en) * 2004-04-30 2016-03-01 The Brigham And Women's Hospital, Inc. Tetracycline-regulated gene expression in HSV-1 vectors
JP5098014B2 (ja) * 2004-11-18 2012-12-12 国立大学法人広島大学 遺伝子増幅により形成された反復配列から、発現抑制されているタンパク質を発現させる方法、キット、および形質転換体
WO2007073513A2 (en) * 2005-11-10 2007-06-28 Genvec, Inc. Method for propagating adenoviral vectors encoding inhibitory gene products
US20080008686A1 (en) * 2006-07-10 2008-01-10 The Brigham And Women's Hospital, Inc. Tetracycline repressor regulated oncolytic viruses
CA2660321A1 (en) * 2006-08-10 2008-02-21 The Board Of Trustees Of The Leland Stanford Junior University Differential labeling of cells
US20090227031A1 (en) * 2007-03-09 2009-09-10 Imre Kovesdi Cells for adenovirus vector and protein production
WO2010075441A1 (en) 2008-12-22 2010-07-01 Trustees Of Boston University Modular nucleic acid-based circuits for counters, binary operations, memory, and logic
US8796440B2 (en) 2009-08-31 2014-08-05 The Brigham And Women's Hospital, Inc. Promote system for regulatable gene expression in mammalian cells
US8809047B2 (en) 2009-12-21 2014-08-19 The Brigham And Women's Hospital, Inc. Herpes simplex virus vaccines
NZ605438A (en) 2010-07-22 2015-02-27 Harvard College Multiple input biologic classifier circuits for cells
ES2931180T3 (es) 2011-05-19 2022-12-27 Fund Publica Andaluza Progreso Y Salud Sistema de tipo Tet-on lentivírico de promotor dual muy inducible
US20150087055A1 (en) 2012-04-13 2015-03-26 Massachusetts Institute Of Technology Analog and mixed-signal computation and circuits in living cells
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
WO2014160025A2 (en) 2013-03-13 2014-10-02 Trustees Of Boston University Tunable control of protein degradation in synthetic and endogenous bacterial systems
EA201591700A1 (ru) 2013-03-14 2015-12-30 Ридженерон Фармасьютикалз, Инк. Гибридные белки апелина и их применение
CN105637085A (zh) 2013-10-11 2016-06-01 瑞泽恩制药公司 代谢优化的细胞培养物
AR102333A1 (es) 2014-08-19 2017-02-22 Regeneron Pharma Selectividad eficiente de proteínas recombinadas
EA035461B1 (ru) 2014-11-04 2020-06-19 Янссен Вэксинс Энд Превеншн Б.В. Терапевтические вакцины против hpv16
EA037295B1 (ru) 2015-08-20 2021-03-05 Янссен Вэксинс Энд Превеншн Б.В. Терапевтические вакцины против hpv18
WO2017059245A2 (en) 2015-09-30 2017-04-06 Trustees Of Boston University Deadman and passcode microbial kill switches
US11261462B2 (en) 2016-01-27 2022-03-01 Just-Evotec Biologics, Inc. Inducible expression from transposon-based vectors and uses
US11028410B2 (en) 2016-01-27 2021-06-08 Just-Evotec Biologics, Inc. Hybrid promoter and uses thereof
US11098310B2 (en) 2016-01-27 2021-08-24 Just-Evotec Biologics, Inc. Expression from transposon-based vectors and uses
MX2018013340A (es) 2016-05-02 2019-08-21 Janssen Vaccines & Prevention Bv Combinaciones de vacunas terapeuticas para el vph.
EP3464332A1 (de) 2016-05-26 2019-04-10 University College Cork - National University of Ireland, Cork Verfahren zur erhöhung der proliferation von säugetierzellen
WO2017203051A1 (en) 2016-05-26 2017-11-30 University College Cork - National University Of Ireland, Cork An engineered gram positive bacterium
KR102111244B1 (ko) 2017-02-09 2020-05-15 얀센 백신스 앤드 프리벤션 비.브이. 이종 유전자의 발현을 위한 강력한 짧은 프로모터
EP3673044A1 (de) 2017-08-25 2020-07-01 University College Cork-National University of Ireland, Cork Bifidobacterium longum zur behandlung von adipositas und gewichtskontrolle
WO2019102018A2 (en) 2017-11-24 2019-05-31 University College Cork, National University Of Ireland, Cork A composition comprising a cohort of bacteria
WO2019152821A1 (en) 2018-02-05 2019-08-08 The Brigham And Women's Hospital, Inc. Recombinant herpes simplex virus-2 expressing glycoprotein b and d antigens
WO2020006409A1 (en) 2018-06-28 2020-01-02 Trustees Of Boston University Systems and methods for control of gene expression
EP3604507A1 (de) 2018-07-30 2020-02-05 University College Cork-National University of Ireland, Cork Omega-transaminase-enzym
AU2020334196A1 (en) 2019-08-20 2022-03-03 Nuritas Limited Peptides for treating muscle atrophy
EP3783012A1 (de) 2019-08-20 2021-02-24 Nuritas Limited Antimikrobielles peptid
JP2022553367A (ja) 2019-10-22 2022-12-22 ニューリタス リミテッド 非アルコール性脂肪肝の治療
WO2021209897A1 (en) 2020-04-13 2021-10-21 Janssen Biotech, Inc. Psma and steap1 vaccines and their uses
EP4070670A1 (de) 2021-04-08 2022-10-12 University College Cork-National University of Ireland Cork Lacticaseibacillus paracasei em025-11 und verwendungen davon
CA3214579A1 (en) 2021-04-14 2022-10-20 Tom Moore Psg1 for use in the treatment of osteoarthritis
JP2024514195A (ja) 2021-04-14 2024-03-28 ユニバーシティ・カレッジ・コークーナショナル・ユニバーシティ・オブ・アイルランド，コーク 脳血管イベントおよび神経障害の治療
WO2024078729A1 (en) 2022-10-14 2024-04-18 University College Cork - National University Of Ireland, Cork Placenta expressed proteins for use in the treatment of tendon injury

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2112130C (en) * 1991-06-27 1996-08-06 Cynthia A. Edwards Screening assay for the detection of dna-binding molecules
WO1993001301A1 (en) * 1991-07-05 1993-01-21 The Penn State Research Foundation Mutant antiviral regulatory proteins
AU683227B2 (en) * 1992-08-26 1997-11-06 Bioscience 2002 Llc Tetracycline repressor-mediated binary regulation system for control of gene expression in transgenic animals
US5589362A (en) * 1993-06-14 1996-12-31 Basf Aktiengesellschaft Tetracycline regulated transcriptional modulators with altered DNA binding specificities
US5464758A (en) * 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5965440A (en) * 1995-12-07 1999-10-12 The General Hospital Corporation Controlled gene product delivery from a regulatable retroviral vector
US5972650A (en) * 1997-06-26 1999-10-26 Brigham And Women's Hospital Tetracycline repressor regulated mammalian cell transcription and viral replication switch

Also Published As

Publication number Publication date
JP3769573B2 (ja) 2006-04-26
US6444871B1 (en) 2002-09-03
DE69835085T2 (de) 2007-01-18
WO1999000510A1 (en) 1999-01-07
CA2293612C (en) 2007-05-08
EP0990041A1 (de) 2000-04-05
JP2005053932A (ja) 2005-03-03
US5972650A (en) 1999-10-26
CA2293612A1 (en) 1999-01-07
EP0990041B1 (de) 2006-06-28
US20020028484A1 (en) 2002-03-07
US6251640B1 (en) 2001-06-26
JP2000515769A (ja) 2000-11-28
ATE331800T1 (de) 2006-07-15
JP2004222733A (ja) 2004-08-12
JP3577323B2 (ja) 2004-10-13
JP3638279B2 (ja) 2005-04-13

Similar Documents

Publication Publication Date Title
DE69835085D1 (de) Regulation der transcription in säugetierzellen und viraler replikation durch eine tetracyclinrepressor
EE04753B1 (et) Rekombinantne MVA viirus ja selle kasutamine, isoleeritud eukarüootne rakk, meetod rekombinantse hTyr-proteiini valmistamiseks ning vaktsiin
ATE172496T1 (de) Wirt-vektor system zur anwendung in gentherapie
FI951404A0 (fi) Adenovirusvektoreita vieraiden geenien siirtämiseksi keskushermostojärjestelmän, erityisesti aivojen, soluihin
ATE323169T1 (de) Plasmid zur verabreichung von nukleine säuren und verwendungsverfahren
ATE231549T1 (de) Verfahren zur konservierung von infektiösen rekombinierenden viren, virale wässrige suspension und ihre medizinische verwendung
DE69834936D1 (de) Vektor zur gewebespezifischen replikation und expression
DE60043547D1 (de) Therapeutische verfahren und zusammensetzungen unter verwendung von viren der rekombinanten familie der paramyxoviridae
WO1995026411A3 (en) Composition and methods for creating syngeneic recombinant virus-producing cells
Razin et al. Nuclear matrix attachment regions and topoisomerase II binding and reaction sites in the vicinity of a chicken DNA replication origin
ATE337406T1 (de) Replikationsunfähige herpesviren zur verwendung in gentherapie
HUP0002913A2 (hu) Eljárások és készítmények szekretált fehérjéket, például béta-interferont kódoló géneket alkalmazó terápiára
DE59510829D1 (de) Gentherapeutisches verfahren unter verwendung von dna-vektoren ohne selektionsmarker-gen
DE602005021159D1 (de) Bakteriophagen- und prophagen-proteine in der krebsgentherapie
KR20040097249A (ko) 중공 나노입자를 형성하는 단백질에 질환 치료용 세포도입 물질을 융합시킨 약제
Norton et al. Expression of secreted platelet-derived growth factor-B by recombinant nonreplicating and noncytopathic vaccinia virus
DK1032429T3 (da) Fremgangsmåde til DNA-afgivelse in vivo ved anvendelse af et nålefrit apparatur
WO2002038188A3 (de) Verwendung der humanen lrp/mvp promotors für einen therapie-induzierbaren vektor
DE60040910D1 (de) Inaktivierte zytokine zur immunisierung
Rosenzweig et al. Delivery Systems for Gene Therapy
WO2003047634A3 (en) Nucleic acids and methods for treating ebv-positive cancers

Legal Events

Date Code Title Description
8364 No opposition during term of opposition